FDA
-
-
-
-
-
-
-
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
-
-
-
-
-
-
-
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
-
-
-
-
-
-
-
IGC Pharma Adds Advisor in Artificial Intelligence
-
-
-
-
-
-
-
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target
-
-
-
-
-
-
-
IGC Pharma (IGC) Granted Patent for Drug Formulation to Treat Agitation in Alzheimer’s
-
-
-
-
-
-
-
IGC Announces Results of its 2023 Annual Stockholders Meeting
-
-
-
-
-
-
-
IGC Pharma Secures $12 Million Line of Credit from O-Bank Strengthening Efforts in Alzheimer's Research
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

